Skip to main content

Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251.

Publication ,  Journal Article
Shacklett, BL; Shaw, KES; Adamson, LA; Wilkens, DT; Cox, CA; Montefiori, DC; Gardner, MB; Sonigo, P; Luciw, PA
Published in: J Virol
November 2002

Attenuated molecular clones of simian immunodeficiency virus (SIVmac) are important tools for studying the correlates of protective immunity to lentivirus infection in nonhuman primates. The most highly attenuated SIVmac mutants fail to induce disease but also fail to induce immune responses capable of protecting macaques from challenge with pathogenic virus. We recently described a novel attenuated virus, SIVmac-M4, containing multiple mutations in the transmembrane protein (TM) intracytoplasmic domain. This domain has been implicated in viral assembly, infectivity, and cytopathogenicity. Whereas parental SIVmac239-Nef(+) induced persistent viremia and simian AIDS in rhesus macaques, SIVmac-M4 induced transient viremia in juvenile and neonatal macaques, with no disease for at least 1 year postinfection. In this vaccine study, 8 macaques that were infected as juveniles (n = 4) or neonates (n = 4) with SIVmac-M4 were challenged with pathogenic SIVmac251 administered through oral mucosa. At 1 year postchallenge, six of the eight macaques had low to undetectable plasma viremia levels. Assays of cell-mediated immune responses to SIVmac Gag, Pol, Env, and Nef revealed that all animals developed strong CD8(+) T-cell responses to Gag after challenge but not before. Unvaccinated control animals challenged with SIVmac251 developed persistent viremia, had significantly weaker SIV-specific T-cell responses, and developed AIDS-related symptoms. These findings demonstrate that SIVmac-M4, which contains a full-length Nef coding region and multiple point mutations in the TM, can provide substantial protection from mucosal challenge with pathogenic SIVmac251.

Duke Scholars

Published In

J Virol

DOI

ISSN

0022-538X

Publication Date

November 2002

Volume

76

Issue

22

Start / End Page

11365 / 11378

Location

United States

Related Subject Headings

  • Virology
  • Viral Load
  • Viral Fusion Proteins
  • Vaccines, Attenuated
  • Vaccination
  • Simian immunodeficiency virus
  • Simian Immunodeficiency Virus
  • Simian Acquired Immunodeficiency Syndrome
  • SAIDS Vaccines
  • Retroviridae Proteins, Oncogenic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shacklett, B. L., Shaw, K. E. S., Adamson, L. A., Wilkens, D. T., Cox, C. A., Montefiori, D. C., … Luciw, P. A. (2002). Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251. J Virol, 76(22), 11365–11378. https://doi.org/10.1128/jvi.76.22.11365-11378.2002
Shacklett, Barbara L., Karen E. S. Shaw, Lou A. Adamson, David T. Wilkens, Catherine A. Cox, David C. Montefiori, Murray B. Gardner, Pierre Sonigo, and Paul A. Luciw. “Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251.J Virol 76, no. 22 (November 2002): 11365–78. https://doi.org/10.1128/jvi.76.22.11365-11378.2002.
Shacklett BL, Shaw KES, Adamson LA, Wilkens DT, Cox CA, Montefiori DC, Gardner MB, Sonigo P, Luciw PA. Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251. J Virol. 2002 Nov;76(22):11365–11378.

Published In

J Virol

DOI

ISSN

0022-538X

Publication Date

November 2002

Volume

76

Issue

22

Start / End Page

11365 / 11378

Location

United States

Related Subject Headings

  • Virology
  • Viral Load
  • Viral Fusion Proteins
  • Vaccines, Attenuated
  • Vaccination
  • Simian immunodeficiency virus
  • Simian Immunodeficiency Virus
  • Simian Acquired Immunodeficiency Syndrome
  • SAIDS Vaccines
  • Retroviridae Proteins, Oncogenic